Investors and Media
     
     
  Events, Presentations and Webcasts
 
Press Releases
 
  Bionovo in the News
 
  Publications
 
  FAQ
 
  Stock Details
 
  Analyst Coverage
 
  SEC Filings
 
  SEC Filings - XBRL Content
 
  Corporate Governance
 
 

BIONOVO, INC.

$N/A (N/A)

BNVI.PK

Press Release

Back

Printer Friendly Version View printer-friendly version

Bionovo to Present at the Cambria Capital Investor Meeting

EMERYVILLE, Calif., April 3 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI), a leader in the discovery and development of safe and effective drugs in the areas of women's health and cancer, is scheduled to present at the Cambria Capital Investor Meeting in Salt Lake City on April 9, 2009 at 3:45 p.m. MST.

Mary Tagliaferri, M.D., President and Chief Medical Officer, is scheduled to present. The purpose of the presentation will be to update investors on the current business developments and goals.

No webcast or archive will be available for this presentation. All interested parties wishing to attend should contact Cambria Capital at (877) 224-0477 toll free, (801) 320-9606 main or by email at clientservices@cambriacapital.com.

About Cambria Capital, LLC

Cambria Capital, LLC ("Cambria") is an investment banking and securities brokerage firm with offices in Salt Lake City, Los Angeles and San Francisco. Cambria's mission is to facilitate the growth and development of promising companies at all stages of development by providing capital and a wide variety of financial advisory services. The financing arranged by Cambria originates from a number of sources, including the firm's principals and Cambria's network of high net-worth individuals and institutional investors. Cambria employs a number of corporate finance structures, including PIPEs (Private Investments in Public Equities), private placements of equity and debt securities and reverse mergers. Cambria is a member of the Financial Industry Regulatory Authority, Inc. ("FINRA"), and the Securities Investor Protection Corporation (SIPC). Visit the Cambria website at http://www.cambriacapital.com.

About Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit: http://www.bionovo.com.

Forward-Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.




    Company Contacts:               Investor Contacts:



    Claire Fong                     Joe Diaz, Robert Blum

    Tom Chesterman                  Joe Dorame

    Tel: 510.601.2000               Lytham Partners, LLC

    investor@bionovo.com            Tel: 602.889.9700

                                    bnvi@lythampartners.com


SOURCE  Bionovo, Inc.



    -0-                           04/03/2009

    /CONTACT:  Claire Fong or Tom Chesterman, both of Bionovo, Inc.,

+1-510-601-2000, investor@bionovo.com; or Joe Diaz, Robert Blum or Joe Dorame,

all of Lytham Partners, LLC, +1-602-889-9700, bnvi@lythampartners.com, for

Bionovo, Inc./

    /Web Site:  http://www.bionovo.com /

    (BNVI)



CO:  Bionovo, Inc.; Cambria Capital, LLC



ST:  California, Utah

IN:  MTC HEA

SU:  TDS WOM



PR

-- LA94608 --

7758 04/03/2009 19:20 EDT http://www.prnewswire.com